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Abstract
Next generation sequencing (NGS) can globally interrogate the genetic composition of biological samples in an
unbiased yet sensitive manner. The objective of this study was to utilize the capabilities of NGS to investigate the
reported association between glioblastoma multiforme (GBM) and human cytomegalovirus (HCMV). A large-scale
comprehensive virome assessment was performed on publicly available sequencing datasets from the Cancer
Genome Atlas (TCGA), including RNA-seq datasets from primary GBM (n = 157), recurrent GBM (n = 13), low-grade
gliomas (n = 514), recurrent low-grade gliomas (n = 17), and normal brain (n = 5), and whole genome sequencing
(WGS) datasets from primary GBM (n = 51), recurrent GBM (n = 10), and normal matched blood samples (n = 20). In
addition, RNA-seq datasets from MRI-guided biopsies (n = 92) and glioma stem-like cell cultures (n = 9) were
analyzed. Sixty-four DNA-seq datasets from 11 meningiomas and their corresponding blood control samples were
also analyzed. Finally, three primary GBM tissue samples were obtained, sequenced using RNA-seq, and analyzed.
After in-depth analysis, the most robust virus findings were the detection of papillomavirus (HPV) and hepatitis B
reads in the occasional LGG sample (4 samples and 1 sample, respectively). In addition, low numbers of virus reads
were detected in several datasets but detailed investigation of these reads suggest that these findings likely
represent artifacts or non-pathological infections. For example, all of the sporadic low level HCMV reads were
found to map to the immediate early promoter intimating that they likely originated from laboratory expression
vector contamination. Despite the detection of low numbers of Epstein-Barr virus reads in some samples, these
likely originated from infiltrating B-cells. Finally, human herpesvirus 6 and 7 aligned viral reads were identified in
all DNA-seq and a few RNA-seq datasets but detailed analysis demonstrated that these were likely derived from
the homologous human telomeric-like repeats. Other low abundance viral reads were detected in some samples
but for most viruses, the reads likely represent artifacts or incidental infections. This analysis argues against
associations between most known viruses and GBM or mengiomas. Nevertheless, there may be a low percentage
association between HPV and/or hepatitis B and LGGs.
Keywords: Human cytomegalovirus, Brain tumors, Gliomas, Meningiomas, Transcriptome analysis
* Correspondence: mware@ochsner.org; erik@tulane.edu
5Department of Neurological Surgery, Ochsner Clinic Foundation, New
Orleans, LA 70112, USA
1Department of Pathology, Tulane University, New Orleans, LA 70112, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Strong et al. Acta Neuropathologica Communications  (2016) 4:71 
DOI 10.1186/s40478-016-0338-z
Introduction
Glioblastoma multiforme (GBM) is the most common ma-
lignant primary brain tumor in adults. An estimated 77,670
new cases of primary CNS tumors are expected to be diag-
nosed in the United States in 2016 [1]. Of these, 24,790 will
be diagnosed as malignant [1]. Although the incidence of
primary brain tumors is low compared to other cancer
types, primary brain tumors give rise to a disproportionate
amount of morbidity and mortality, often robbing patients
of basic and critical functions such as movement and
speech [2]. The median survival of newly diagnosed pa-
tients is only 12–15 months, making it one of the most
devastating types of cancers [3]. In fact, the five-year sur-
vival rate for primary malignant brain and central nervous
system tumors is the sixth lowest among all types of can-
cers after pancreatic, liver & intrahepatic bile duct, lung,
esophageal, and stomach [2]. Unfortunately, despite sub-
stantial investigations into disease mechanisms and at least
some advances in currently available treatment options,
the outcomes for GBM patients remain dismal [3].
Although an association between human cytomegalovirus
(HCMV) and GBM was first observed in 2002 [4], there is
still a high degree of discordance in the literature regarding
the detection of viral agents in CNS tumors [4–28]. These
discrepancies have been attributed to a number of issues
including the use of different cohorts, differences in sensi-
tivities of different PCR assays for low levels of viral gene
expression, and the exquisite sensitivities of assays such as
IHC to slight differences in experimental conditions.
In an attempt to remedy the high degree of discord-
ance regarding the detection of HCMV in CNS tumors,
an HCMV and glioma symposium was convened in
Washington, DC on April 17, 2011. At the conclusion of
this workshop, a summary paper was published reporting
the consensus position in 4 major areas: 1) the existence
of HCMV in gliomas, 2) the role of HCMV in gliomas, 3)
HCMV as a therapeutic target, and 4) key future investiga-
tive directions [29]. Based on the evidence presented at
the workshop, it was concluded that HCMV sequences
and viral gene expression exist in many malignant gliomas
and that in vitro studies support the idea that HCMV can
modulate key signaling pathways in glioblastomas [29].
Next generation sequencing (NGS) has the ability to
globally interrogate the genetic composition of biological
samples in an unbiased manner and with relatively high
sensitivity. Applying this technology to pathogen discov-
ery has already shown promise, resulting in the discov-
ery of a novel Merkel cell polyomarvirus in Merkel cell
carcinoma [30], for example. In our laboratory, we have
utilized NGS technology in the interrogation of Epstein-
Barr virus (EBV) in diffuse large B-cell lymphomas [31]
and gastric carcinoma [32]. The goal for the study pre-
sented here was to help resolve the lingering controversy
pertaining to the presence of HCMV in GBM while at
the same time providing a comprehensive and unbiased
assessment of the viral genetic composition of brain
tumor biopsies. This analysis failed to find convincing
evidence for an association between HCMV or other
known viruses and GBM or mengiomas. Nevertheless,
we detected human papillomavirus (HPV) and hepatitis
B in some low-grade gliomas (LGG). In addition, we
expand on our previous reporting of potential contami-
nation and/or interpretational artifacts that need to be
considered in next generation sequencing based metage-
nomic and metatranscriptomic studies [33, 34].
Materials and methods
Clinical tumor sample and sequence data acquisition
All human specimens were de-identified prior to acquisi-
tion. Fresh frozen tissue from 1 GBM sample was obtained
from the Louisiana Cancer Research Consortium (LCRC)
Biospecimen Core. Additionally, RNA isolated from 2 GBM
samples were obtained from BioServe. An RNA-seq dataset
from a lymphoblastoid cell line immortalized with EBV (JY)
was used as a control for downstream analysis [35].
Publically available sequence datasets were obtained
from various sources. Next generation sequencing datasets
from The Cancer Genome Atlas (TCGA) initiative were
downloaded from the Cancer Genomics Hub (CGHub;
https://cghub.ucsc.edu) and included RNA-seq datasets
(unaligned fastq files) from primary GBM tumors [36–38]
(n = 157), recurrent GBM tumors (n = 13), low grade
gliomas [39] (LGG; n = 514), recurrent low grade gliomas
(n = 17), and normal brain (n = 5), and TCGA whole gen-
ome sequencing datasets (aligned bam files) from primary
GBM tumors (n = 51), recurrent GBM tumors (n = 10),
and normal matched blood samples (n = 20) (Additional
file 1: Table S1). The aligned bam files were converted to
fastq files using bam2fastq (https://gsl.hudsonalpha.org/
information/software/bam2fastq, default parameters).
Additional brain tissue sequencing datasets were ob-
tained from the NCBI Sequence Read Archive (Additional
file 1: Table S1). RNA-seq datasets from tumor and per-
ipheral brain tissue of a GBM patient were obtained using
accession number SRP009144 [40]. Normal brain tissue
RNA-seq dataset from the Illumina Human Body Map
2.0 project was obtained using (NCBI GEO accession
GE30611). RNA-seq datasets from a cohort of short-
term cultures of glioma stem-like cells freshly isolated
from nine patients diagnosed with primary GBM were
downloaded using accession number SRP016798 [41,
42]. A cohort of RNA-seq datasets from MRI-localized
biopsies of the tumor core and margins from multiple
glioma patients and non-neoplastic brain tissue speci-
mens were downloaded using accession number
SRP044668 analyzed [43]. Non-neoplastic brain tissue
samples were obtained from multiple patients undergo-
ing procedures to alleviate epilepsy symptoms or to
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place shunts to treat normal pressure hydrocephalus. In
total, RNA-seq datasets from 39 contrast-enhancing gli-
oma core samples, 36 non-enhancing FLAIR glioma
margin samples, and 17 non-neoplastic brain tissue
samples were analyzed. A cohort of 64 whole genome
sequencing datasets from 11 Grade I meningiomas and
11 matched blood samples were obtained using acces-
sion number SRP016129 [44]. Finally, RNA-seq datasets
from HCMV infected fibroblasts were downloaded
using accession number SRP016143 [45].
Sample preparation and next generation RNA sequencing
Total RNA was extracted from 3 primary GBM biopsies
(00RTS3 – from the LCRC biospecimen core; and
CAURPRVE and H8CPFRSJ – from Bioserve) using Tri-
zol (Invitrogen, Carlsbad, CA) according to manufac-
turer’s instructions. Total RNA from sample 00RTS3
was subjected to polyA selection, and the library was pre-
pared using the ScriptSeq Protocol (Epicentre, Madison,
WI) and subjected to 2x101 base paired-end sequencing
on an Illumina Hi-seq 2000 machine. Total RNA from
samples CAURPRVE, H8CPFRSJ, and JY were subjected
to ribosomal RNA depletion using the Ribo-Zero kit
(Epicentre, Madison, WI) and cDNA libraries were pre-
pared using the Illumina Truseq Stranded Total RNA
Sample Prep Kit and subjected to 1x101 base single-
end multiplexed sequencing on an Illumina Hi-seq
2000 machine. The RNA-seq data used in this publica-
tion is available through GEO Series accession number
(in process).
Metatranscriptomic analysis using RNA CoMPASS
Metatranscriptome analysis was performed by running
single-end or one pair from paired-end sequencing data
through our automated RNA-seq exogenous organism
analysis software, RNA CoMPASS [46]. Within RNA
CoMPASS, reads were aligned to the human reference
genome, hg19 (UCSC), plus a splice junction database
(which was generated using the make transcriptome
application from Useq [47]; splice junction radius set to
the read length minus 4) using Novoalign V3.00.05
(www.novocraft.com) [−o SAM, default options]. Non-
mapped reads were subjected to a BLAST V2.2.30
search against the Human RefSeq RNA database to iden-
tify and remove human reads that fail to be identified
through the Novoalignment. Remaining non-human reads
were then subjected to a BLAST V2.2.30 search against
the NCBI NT database to identify reads corresponding to
known exogenous organisms [48]. Results from the NT
BLAST searches were filtered to eliminate matches with
an E-value of greater than 10e−6. The results were then
fed into MEGAN 4 V4.70.4 for visualization of taxonomic
classifications [49]. RNA CoMPASS was run in parallel on
three 2x2.66 GHz 12 core Intel Xeon Mac Pro computers
with 64-96GBs of memory each.
Virome analysis
Raw sequence data from RNA-seq and DNA-seq were
aligned to a reference containing a human genome
(hg19; Genome Reference Consortium GRCH37) plus a
library of 740 virus genomes (including sequences from
all known human viruses documented by NCBI) [50].
The alignments were performed using Spliced Tran-
scripts Alignment to a Reference (STAR) aligner version
2.3.0 [−−clip5pNbases 6 (only used if reads were longer
than 36 base pairs), default options] [51]. Uniquely mapped
viral and human reads were quantified using in-house
computational pipelines. Signal maps (i.e. the total number
of reads covering each nucleotide position) from viruses of
interest were generated using IGV tools and were sub-
jected to manual visual inspection using the IGV genome
browser [52].
Quantitative RT-PCR
Total RNA was reverse-transcribed using the Super-
Script III First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, CA). Random hexamers were used
with 1 ug total RNA in a 20 μl reaction volume accord-
ing to manufacturer’s instructions. For the incubation
steps (25 °C for 10 min followed by 50 °C for 50 min) a
Mastercycler ep (Eppendorf, Hamburg, Germany) was
used. For real-time PCR, 1 μl of the resulting cDNA
(diluted to 10 ng/ul) was used in a 10 μl reaction mix-
ture that included 5 μl of 2x iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA), 1 μl of 10 μM forward and
reverse primer mix (Integrated DNA Technologies,
Coralville, IA), and 3 μl of PCR grade water.
A list of PCR primer oligos can be found in Additional
file 2: Table S2. Each sample was PCR’ed in triplicate.
No-template controls and no-reverse transcription con-
trols were also included in each PCR run. Thermal cycling
was performed on a CFX96 Real Time System (Bio-Rad,
Hercules, CA) and data analysis was performed using the
CFX Manager 3.0 software. Cycling conditions included
an initial incubation at 95 °C for 3 min followed by 40 -
cycles consisting of 95 °C for 15 s, and 60 °C for 60 s.
Melting curve analysis was performed at the end of every
qRT-PCR run.
Results
Lack of virus association in the cancer genome atlas GBM
RNA-seq datasets
Previous studies have used human read subtraction-
based approaches to assess the metatranscriptomic pro-
file of primary and recurrent glioma RNA-seq datasets
from The Cancer Genome Atlas (TCGA) where a lack
of association with HCMV was reported [10, 14, 26, 27].
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To investigate this issue further, we first performed a
global virome analysis on these samples (as well as 5
normal brain tissue samples), using a more directed,
non-subtraction based approach that we have reported
previously [33, 50, 53]. For this analysis, we directly
aligned all reads from these datasets to an alignment
index containing the human genome plus a library of
740 virus genomes (including sequences from all known
human viruses documented by NCBI) using the Spliced
Transcripts Alignment to a Reference (STAR) aligner.
Running this virome pipeline on a known EBV-associated
gastric cancer tissue biopsy cohort from TCGA [54]
showed EBV read levels which ranged from 7–400 viral
Reads Per Mapped Human reads (RPMH) [53]. Like PCR,
next generation sequencing is susceptible to low level con-
tamination issues [34]. Nevertheless, in an attempt to cap-
ture potential low abundance infections, we set a viral
read threshold that was 10 times lower than the lowest
viral RPMH value for EBV in the gastric cancer cohort
[53, 54]. Based on this requirement of at least 0.7 viral
RPMH, no virus associations were called in 157 primary
and 13 recurrent gliomas or in 5 normal brain RNA-seq
datasets analyzed except for the finding of 2.1 human her-
pesvirus (HHV) -6 or HHV-7 RPMH (note: HHV-6 and
HHV-7 reads are considered together here due to all reads
mapping to a homologous region of these two viruses) in
one recurrent glioma (Fig. 1, Additional file 3: File S1).
Notably, all HHV6/7 reads in this sample were found
to contain the simple sequence, TAACCC, a repeat
found in both of these virus genomes and in human
telomeric repeats. Since no HHV6/7 assigned reads
mapped outside of the TAACCC repeat region of the
viral genomes, we conclude that these reads likely origi-
nated from contaminating genomic sequences from
human telomeric repeats.
Analysis of RNA-seq data from a cohort of time
course HCMV infected fibroblasts [45] demonstrated
robust numbers of HCMV reads (ranging from 68,875 –
578,635 RPMH) that escalated roughly proportionally to
the length of infection (Additional file 4: File S2). Since
our detection cutoff of 0.7 RPMH for TCGA cohort is
about 5 to 6 orders of magnitude less than these read
numbers, this data supports a lack of association between
HCMV and GBMs.
Assessment of sequence library preparation strategies
Although the bulk of viral RNAs are polyadenylated,
some viral transcripts are not. To assess whether we
were missing viral infections because of a lack of detect-
ing non-polyadenylated viral transcripts, we wanted to
test whether sequencing of ribodepleted RNAs (versus
polyA selected RNAs as per the TCGA cohort) might
yield the detection of viral reads. HCMV has been re-
ported to have a high penetrance in GBM with some
studies reporting as high as 90–100 % positivity [4, 17,
19, 24, 29]. We sequenced two of our own GBM samples
using ribosomal depleted RNA as well as an additional
sample using poly-A selected RNA. Because virome ana-
lysis was not previously performed on these samples, we
implemented two virus detection approaches. First we
analyzed each of these samples through our custom
subtraction based pathogen detection pipeline, RNA
CoMPASS, which analyzes the entire metatranscriptome.
For a more focused virome analysis, we then imple-
mented the STAR aligner approach.
No associations were found with any known viruses in
the polyA selected RNA sample (00RTS3) (Fig. 1) using
either RNA CoMPASS (Additional file 5: Figure S1) or
the STAR/virome analysis approach (Additional file 6:
File S3). Additional publically available poly-A selected
RNA datasets from a GBM study, in which they se-
quenced one primary GBM and the matched normal
brain, and a normal brain sample from the BodyMap
project were obtained and analyzed. Assessing these
public poly-A selected RNA datasets similarly showed
no association with any known virus (Fig. 1, Additional
file 5: Figures S2, S3 and S4).
Analysis of the ribosomal depleted RNA samples
(CAUPRVE and H8CPFRSJ) revealed reads from the
murine leukemia virus (MuLV) family (2.4 and 4.3 RPMH,
respectively) and a low abundance of EBV reads (0.8 and
1.9 RPMH, respectively) (Additional file 6: File S3 and
Additional file 5: Figures S5 and S6). Further analysis of
the viral read coverage for MuLV and EBV demonstrated
near identical coverage patterns to another sample (JY –
an EBV-immortalized B cell lymphoblastoid cell line,
which we have previously shown to be infected with
MuLV [35]) that was sequenced in the same sequencing
lane (Additional file 5: Figure S7). Our suspicion of
Fig. 1 Heat map showing the number of viral reads per million human mapped (RPHM) reads for brain tissue RNA-seq datasets. Color intensity
represents relative viral RPHM across all datasets
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contamination across barcodes was confirmed by real-
time PCR for samples CAUPRVE and H8CPFRSJ, in
which neither MuLV nor EBV transcripts were detected
(Additional file 5: Figure S8). Real-time RT-PCR for
HCMV transcripts were similarly negative in these sam-
ples, thus confirming the lack of RNA-seq based HCMV
findings in these datasets.
Analysis of tumor tissue sampling
Since GBM is a very heterogeneous solid tumor, differen-
tial sampling of the tumor mass may result in different
transcriptomic and metatranscriptomic profiles. To take
this issue into account for the detection of HCMV, we
took advantage of a well-designed study in which the
authors sequenced MRI-localized biopsies of the tumor
core and margins from multiple GBM patients. The
authors also sequenced several non-neoplastic brain tissue
samples [43]. Virome assessment of this cohort using
RNA CoMPASS detected no viruses (Additional file 5:
Figures S9 – S102). Assessment of this cohort using the
STAR/virome approach detected Human Immunodefi-
ciency virus type 1 (HIV-1) at levels greater than 0.7 viral
RPMH in 2 glioma samples (5.3 and 5.5 RPMH) taken
from the non-enhancing FLAIR portion (margins) of the
tumor and 2 glioma samples (3.1 and 4.2 RPMH) taken
from the contrast enhancing portion (core) of the tumor
(Additional file 6: File S3). To investigate these findings
further, we analyzed the genome coverage of HIV reads in
these samples plus three samples that showed HIV read
levels that are below our 0.7 RPMH threshold (1 non-
neoplastic sample (0.37 RPMH) and 2 additional contrast
enhancing core samples (0.04 and 0.16 RPMH)). Inspec-
tion of the HIV-1 read coverage from all seven glioma
samples revealed that the majority of the HIV-1 reads
aligned to the long terminal repeat regions and additional
homologous regions of the expression vector pH1TO, as
shown in Additional file 5: Figure S103. MuLV reads were
also detected in 33 out of the 36 glioma samples (0.03 –
5.74 RPMH) taken from the non-enhancing FLAIR
portion of the tumor, 35 out of the 39 glioma samples
(0.03 – 12.72 RPMH) taken from the contrast enhancing
portion of the tumor, and 15 out of the 17 non-neoplastic
samples (0.03 – 3.33 RPMH) (Additional file 6: File S3).
Inspection of the MuLV read coverage showed a sporadic
genomic coverage pattern that was similar across the
tumor samples (Additional file 5: Figures S104-S106). The
observed similar coverage profiles, the finding of low read
numbers, and our previous observations of sample cross
contamination of human samples with MuLV, lead us to
suspect that the MuLV read findings here are most likely
due to cross contamination. Finally, although the level
of HCMV reads did not exceed 0.7 viral RPMH in any
given sample, for completeness, all detected HCMV
reads including those from 14 glioma samples from
non-enhancing FLAIR portions (0.03 – 0.21 RPMH)
and 12 glioma samples from contrast enhancing por-
tions (0.04 – 0.25 RPMH) were analyzed further. All
HCMV reads were found to align to the HCMV imme-
diate early promoter (Additional file 5: Figures S107
and S108). As mentioned above for the HCMV findings
in the TCGA cohort, this is suggestive of sample contam-
ination with laboratory expression plasmids bearing the
HCMV promoter. After accounting for the artifactual viral
reads, we conclude that this cohort shows no likely associ-
ation with any known viruses (Fig. 1).
Analysis of GBM stem cell subpopulations
Due to the low abundance and limited detection of HCMV
in GBMs reported in the literature, some groups have pro-
posed that HCMV is harbored in only a small number of
tumor cells, specifically the CD133+ tumor stem cells
[55–57]. To address this possibility, we analyzed RNA-seq
datasets generated from a cohort of short-term glioma
stem-like cell cultures freshly isolated from nine patients
diagnosed with primary GBM. Analysis of these datasets
using our STAR/virome pipeline showed the detection of
human Adenovirus C (HAdV-C) in 9 out of the 24 samples
with the remaining 15 samples showing low abundance
HAdV-C read levels Additional file 6: File S3 and Add-
itional file 5: Figures S109-S132. HAdV-C was also detected
in the same 9 samples using RNA CoMPASS (Additional
file 5: Figures S112-S132). Despite detecting HAdV-C in
these samples, viral read coverage was primarily limited to
the same three small regions of the genome in the majority
of samples (Additional file 5: Figure S133). Further manual
blast analysis of the HAdV-C reads demonstrated hom-
ology with laboratory adenovirus vectors (data not shown).
Although we detected only low level HCMV reads in 3 gli-
oma stem-like cell culture samples (0.03 – 0.1 RPMH), we
further analyzed these reads due to the historical signifi-
cance of this virus with GBM. Similar to our previous
HCMV findings discussed above, viral read coverage ana-
lysis again showed that all reads aligned with the HCMV
IE1 promoter (Additional file 5: Figure S134). RNA CoM-
PASS analysis did not identify HCMV reads in these sam-
ples (Additional file 5: Figures S112-S113 and S131).
Virome analysis of TCGA low-grade gliomas
To study the virome of low-grade gliomas (LGG), RNA-
seq datasets from 514 primary and 17 recurrent LGGs
from the TCGA were analyzed [39]. Due to the magnitude
of the sample number, we exclusively used the sensitive
yet rapid approach of our STAR/virome method. Based on
this analysis, Human Papillomavirus (HPV) 16 was de-
tected in 3 out of the 514 samples (1.5 – 2.4 RPMH), al-
though lower HPV-16 read numbers were observed in 22
additional samples (Fig. 1 and Additional file 7: File S4).
Inspection of HPV-16 read coverage for the 3 positive
Strong et al. Acta Neuropathologica Communications  (2016) 4:71 Page 5 of 10
samples showed expression of the HPV-16 E6 and E7 onco-
genes with lower coverage of the E1, E2 and E4 regions
(Additional file 5: Figure S135). The lack of any coverage of
the right half of the HPV-16 genome is consistent with de-
letion of this region which is frequently observed in onco-
genic HPV genome integrations (where viral integration
and the concomitant deletion of these negative regulatory
genes results in increased expression of the oncogenic E6
and E7 genes while at the same time preventing productive
viral infection and host cell destruction). We also detected
HPV-58 in 1 sample (1.9 RPMH) with lower HPV-58 reads
in 2 additional samples (Fig. 1 and Additional file 7: File
S4). Inspection of viral read coverage for the HPV-58 posi-
tive samples showed that the single sample with read levels
above the 0.7 RPMH threshold had good read coverage of
the E6, E7, and the E2/E4/E5 region (Additional file 5:
Figure S136). Finally, Hepatitis B reads were detected in 1
sample (13 RPMH), although below threshold Hepatitis B
reads were detected in 2 additional samples (Fig. 1 and
Additional file 7: File S4). Inspection of Hepatitis B read
coverage for the above threshold sample showed good
read coverage within the HBVgp1/HBVgp2/HBVgp3 re-
gion where coverage abruptly stops. Furthermore, the
majority of HBV reads align to the HBVgp3 gene, which
encodes the regulatory HBx protein (Additional file 5:
Figure S137). Like the above findings of read mapping
being primarily limited to viral HPV oncogenes, the HBV
mapping data are suggestive of oncogenic viral integra-
tion. No virus associations were observed with the 17
recurrent LGGs (Fig. 1 and Additional file 7: File S4).
Lack of virus association in the cancer genome atlas GBM
whole genome datasets
To explore the possibility that viruses infecting brain tissue
become transcriptionally dormant, resulting in the lack of
virus detection in RNA-seq datasets, we subjected the
TCGA GBM whole genome sequencing (WGS) datasets to
our virome analysis pipeline.
Analysis of viruses at the DNA level was relatively un-
remarkable with the highest read numbers in the pri-
mary (TP) GBM WGS datasets being derived from EBV
and HAdV-C (Fig. 2 and Additional file 8: File S5). The
highest viral read numbers identified in a recurrent (TR)
GBM WGS datasets was derived from EBV with 1,454
total viral reads (Fig. 2). Two HCMV viral reads were de-
tected in 1 TP GBM WGS dataset (TCGA-14-1823) but
not the corresponding blood matched normal (N) con-
trol. Manual blast of these HCMV reads from the tumor
demonstrated homology to HCMV laboratory expres-
sion vector sequences (Additional file 9: File S6), which
was also demonstrated by Tang et al. [27].
EBV reads were detected in 9 TP GBM WGS datasets
for which 6 out of 9 samples analyzed had correspond-
ing blood matched samples (Additional file 8: File S5).
We detected EBV in 4 additional normal blood samples
and 3 TR GBM WGS datasets (Additional file 8: File
S5). Upon further analysis of the raw EBV reads from
the TP GBM datasets, the viral reads were found to be
homologous to the EBV genome based on blasting ana-
lysis (Additional file 9: File S6). EBV read coverage
analysis for the 3 TR GBM samples displayed viral gen-
ome coverage across the entire genome for 2 of the sam-
ples (Additional file 5: Figure S138). Torque Teno Virus
reads were incidentally identified in three normal blood
samples. Finally, although a high level of HHV- 6 and 7
reads were detected in all WGS samples, manual inspec-
tion of the raw sequence reads showed that they are
likely derived from human chromosomal telomeric-like
repeats, TAACCC (data not shown).
Lack of virus association in meningioma whole genome
datasets
To determine if other brain tumors are associated with
viruses, we analyzed 64 WGS datasets from 11 patients
with grade I meningiomas and their matched blood con-
trol samples. Analysis of the WGS datasets from the
meningioma samples demonstrated no confirmed associ-
ation with viruses (Fig. 2 and Additional file 10: File S7).
Similar to our analysis of the TCGA GBM WGS data-
sets, a low abundance of EBV reads were detected in 3
tumor samples and 4 normal blood samples, raising the
possibility that these reads came from infiltrating B-cells.
Furthermore, HHV-6 and HHV-7 reads were detected in
all 22 samples but consisted of the simple sequence re-
peat, TAACCC suggesting that these reads likely origi-
nated from human telomeric repeats (data not shown).
Discussion
Although there was an agreement reached from the
HCMV/GBM symposium in 2011, emerging studies
using NGS to assess the viral association with GBM has
been unable to recapitulate this association [9, 10, 14,
26, 27]. In line with these previous studies, our data fur-
ther supports no direct viral association with GBM.
There may be a possible association of HPV-16, HPV-
58, and Hepatitis B with LGGs, however additional val-
idation studies are required before any conclusions can
be drawn from our initial assessment. Furthermore,
based on the low abundance of viral reads that were
identified in these cases, whether these viruses are truly
associated with LGGs and not derived from sequencing
contamination is unclear. Finally, although the viral
detection threshold that we set for the RNA-seq datasets
is relatively low (0.07 RPMH), all HCMV read findings
were analyzed further irrespective of how low the HCMV
read level and were found to be likely derived from labora-
tory plasmid contamination.
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The hallmark of herpesviruses, and their key to per-
sistence within their host, is their ability to switch to
highly restricted gene expression patterns that allow
avoidance of the immune system. To overcome the po-
tential problem of missing viral infections due to this
type of viral adaptation, WGS datasets were analyzed.
Nevertheless, this approach also failed to identify any
meaningful virus associations in the analyzed samples.
This is in contrast to a report by Amirian et al. in which
they identified HHV-6A and HHV-6B in the WGS data-
sets from TCGA [5]. Another study conducted by Cimino
et al. also identified HHV-6 and EBV DNA when they an-
alyzed unmapped reads from a NGS-based comprehensive
oncology panel [9]. Although our initial investigation de-
tected the presence of HHV-6 and HHV-7 viruses, further
analysis of these viral reads revealed all reads consisted of
human chromosomal telomeric-like repeats, TAACCC.
Although HHV 6 and 7 have sequences homologous to
this region, no other regions of the viral genome were rep-
resented in the sequence datasets. This is highly suggestive
that these reads originated from the telomeric region of
human chromosomes rather than representing bona fide
HHV6 or HHV7 infection.
EBV DNA reads were identified in a number of the
TCGA DNA-seq datasets including 9 TP GBM WGS
samples, 6 normal matched blood WGS samples plus 4
additional normal blood WGS samples, and 3 TR GBM
WGS samples. In addition, we identified EBV DNA reads
in 3 grade I meningioma samples and 4 normal blood
samples. All EBV DNA reads identified were low in abun-
dance with 1 – 39 reads detected in primary GBM
samples, 1–5 reads detected in normal blood samples, and
1 – 15 reads detected in grade 1 meningiomas, a result
similar to the findings of Cimino et al. in which they iden-
tified 1 – 18 EBV reads in 5 GBM samples [9]. We identi-
fied 3 TR GBM samples using WGS datasets that were
EBV positive, with 1 of these datasets showing moderate
EBV levels (1454 viral reads), another showing minimal
EBV levels (80 viral reads), and the last dataset had 1 EBV
viral read. Although these three TR GBM WGS datasets
were positive for EBV, the corresponding RNA-seq
datasets for these samples failed to validate these findings.
Without tissue to confirm these findings, it is impossible
to determine the origin of these viral reads and we do not
feel confident in associating EBV with these TR GBM
samples. In addition, based on our past experience in the
field of EBV, if EBV was truly associated, we would likely
see greater than 10 viral RPMH for RNA-seq and thou-
sands of viral reads for DNA-seq [32, 53]. Finally, given
the ubiquitous nature of EBV, the low viral read counts,
and the presence of EBV in both tumor and blood samples
in relatively equal proportions, we postulate that the EBV
reads that were detected likely originated from EBV
infected B-cells localized in the tumor stroma and/or from
library or sequencing sample cross-contamination.
Due to the nature of GBM, there is a possibility for a
preponderance of necrotic tissue within the tumor bulk,
resulting in the effective dilution of tumor cells and
tumor associated viruses; which could be argued as an
explanation for the lack of strong viral detection. How-
ever, given the large number of samples analyzed and
the careful procurement protocols utilized by TCGA, it
is unlikely that the majority of samples fall within this
scenario. Further supporting this contention, our ana-
lysis of the MRI-localized GBM biopsies from Gill et al.
[43] did not detect any known viruses and there were no
differences between samples obtained from the core
(presumably more necrotic) and those samples obtained
from the tumor margin (presumably less necrotic, with
active tumor growth and neoangiogenesis).
The identification of HPV-16, HPV-58 and HBV in a
small portion of LGG RNA-seq datasets is a potentially in-
teresting finding. Analysis of the clinical data from these
patients using cBioPortal [58, 59] demonstrated that the
majority of virus positive samples were oligodendrogliomas
(3 out of the 5 samples) from White males with an average
age of 42 (Additional file 11: File S8). The demographics
are relatively consistent with the whole LGG cohort (55 %
males, 92 % White, and average age 43). Tumor type varied
slightly from the whole cohort, which consisted of 193 as-
trocytomas (38), 130 oligoastrocytomas (25), and 191
oligodendrogliomas (37 %). In addition, although the
Fig. 2 Heat map showing the total reads for brain tissue whole genome sequencing datasets. Color intensity represents relative viral reads across
all datasets
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genetic profile of these patients demonstrates a variety of
alterations, some of the more common alterations ob-
served in the entire cohort (e.g., IDH1, IDH2, ATRX, and
TP53) were not observed in these patients with HPV or
HBV reads (see reference [39] for additional details regard-
ing LGG samples). The lack of mutation of one or more of
these in tumors with detected virus could be due to viral
subversion of the corresponding pathways, obviating the
need for somatic mutations (for example, through HPV E6
mediated inhibition of the p53 pathway). Nevertheless,
further investigation into the association between viruses,
HPV and HBV and LGGs is warranted.
Both HPV-16 and HPV-58 are considered high-risk
HPV types, which are causative agents in the develop-
ment of cervical carcinoma. The likely mechanism of
action for both HPV-16 and HPV-58 is viral integration
into the host genome [60, 61]. Coverage analysis of the
HPV positive LGG datasets indicate that some of the sam-
ples display evidence of integration with disruption of the
viral E1 gene (Additional file 5: Figures S135-136) with all
samples with HPV reads showing the majority of read
coverage mapping to viral E6 and E7 oncogenes. Due to the
low viral read numbers detected in our study, additional
validation experiments are warranted to determine if there
is truly an association between LGGs and HPV or whether
these findings represent sample cross-contamination with
true HPV associated samples.
Like HPV, the mechanism of action for HBV is also in-
tegration into the host genome. Visual analysis of the
HBV positive LGG datasets demonstrated robust gene
coverage within the HBVgp1/HBVgp2/HBVgp3 region
with an abrupt termination of gene coverage after HBVgp3
(Additional file 5: Figure S137). Further, the majority of
reads align within the HBVgp3 gene, which encodes the
regulatory HBx protein. Previous studies have shown that
HBx plays a critical role in the pathogenesis of hepatocellu-
lar carcinoma [62, 63]. While this observation is also of po-
tential interest, given the fact that adequate HBV reads
were detected in only 1 sample out of 514 LGG datasets
(0.19 %), further analysis is necessary to validate this
observation.
The RNA CoMPASS analysis of the auxiliary brain tis-
sue sequencing datasets provided a full metatranscrip-
tomic profile including bacterial, fungal, and viral reads.
Although we only presented data on the virome in this
study, a complete metatranscriptomic analysis was per-
formed. Although reads for several bacterial species were
identified in the datasets, it has been our experience that
the source of many of these reads are from environmen-
tal contamination [33, 34, 64] and do not represent true
associations.
Due to reports of an association between HCMV and
GBM, immunotherapy treatments against HCMV were
considered a logical next step as an exhilarating new
avenue for cancer therapy. There are several clinical tri-
als in the United States in various stages of completion
focused on targeted HCMV therapy in GBM patients.
While we await the results of these clinical trials, the re-
sults from the valganciclovir treatment of glioblastoma
patients in Sweden (VIGAS) study, a randomized, double-
blinded, placebo-controlled trial was recently published
showing trends but no significant differences in tumor
volumes between the valganciclovir (an anti-CMV drug)
and placebo groups at 3 and 6 months [65]. However, in a
retrospective analysis of the same cohort with additional
patients taking valganciclovir for compassionate reasons,
the rate of survival of treated patients at 2 years was 62 %
as compared with 18 % of contemporary controls with a
similar disease stage, surgical-resection grade, and baseline
treatment [66]. Although these are remarkable results,
questions have been raised as to the interpretation of the
data and whether this survival rate is misleading [67].
Conclusions
Several recent publications have highlighted the lack of
association between viruses, specifically HCMV, and GBM
[6, 10, 14, 15, 18, 26–28, 68]. Based on our comprehensive
analysis, we substantiate these claims. Given the austerity of
recent evidence against a HCMV etiology for GBM, moving
forward, we caution against the use of anti-CMV therapy
for GBM patients until this issue is completely resolved.
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